By Fineline Cube 
Rock Roc Biotechnology Co., Ltd completed an oversubscribed RMB 50 million (≈ US$7 million) Series A financing to advance its world‑leading macrophage‑based therapy platform, including its third‑generation CAR‑M pipeline targeting HER2 and pipelines for pancreatic and lung cancers.
Financing Details
| Item | Detail |
|---|---|
| Company | Rock Roc Biotechnology Co., Ltd |
| Amount | RMB 50 million (≈ US$7 million) |
| Round | Series A (oversubscribed) |
| Use of Proceeds | Build macrophage drug platform; accelerate IND/Phase I for HER2 CAR‑M; advance preclinical/IIT for pancreatic/lung cancer pipelines |
| Next Catalyst | IND submission for HER2 CAR‑M expected H2 2026 |
Technology Profile
- Core Platform: Macrophage‑specific viral modification technology achieving >90% transduction efficiency , solving the industry‑wide CAR‑M gene delivery challenge
- 3rd‑Gen CAR‑M: First‑in‑class tandem design incorporating cytokines essential for macrophage auto‑proliferation and activation, promoting long‑term survival and tumor microenvironment modification
- Clinical Validation: Completed IIT clinical trials in 10 patients with HER2‑positive solid tumors
- Iterative Delivery System: Proprietary technology functionally acts as a “next‑generation operating system” , enabling any nucleic acid‑based drug to achieve performance leaps when loaded onto the platform
Pipeline Summary
| Program | Target/Indication | Stage | Next Milestone |
|---|---|---|---|
| HER2 CAR‑M | HER2‑positive solid tumors | Pre‑IND | IND submission H2 2026 |
| Pancreatic Cancer CAR‑M | Undisclosed target | Preclinical | IIT initiation 2027 |
| Lung Cancer CAR‑M | Undisclosed target | Preclinical | IIT initiation 2027 |
Market Impact & Outlook
- CAR‑M Landscape: Macrophage cell therapies represent an $8‑12 billion potential market by 2035, targeting solid tumors where T‑cell CARs face microenvironment barriers. Rock Roc’s >90% transduction efficiency positions it ahead of peers like CARISMA Therapeutics (30‑50% efficiency) and Myeloid Therapeutics (preclinical stage).
- HER2 Opportunity: HER2‑positive cancers (breast, gastric, lung) affect ~500,000 patients annually in China; CAR‑M could capture 10‑15% of patients failing ADCs and TKIs, representing a ¥2‑3 billion addressable market.
- Revenue Forecast: Analysts project Rock Roc could achieve ¥800 million‑1.2 billion (~US$110‑165 million) peak China sales by 2032, assuming first‑mover advantage and 25% market share in HER2 CAR‑M segment.
- Strategic Value: The “next‑gen OS” delivery platform creates partnering opportunities across gene therapy and mRNA fields; potential licensing deals could generate US$50‑100 million in upfront payments.
- Financing Runway: RMB 50 million funds operations through Q4 2026, after which a Series B (estimated US$30‑40 million ) will be required to fund Phase I trials and platform expansion.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Rock Roc’s technology development, clinical timelines, and commercial potential. Actual results may differ materially due to risks including preclinical-to-clinical translation, manufacturing scale‑up, competitive dynamics, and regulatory pathways for novel cell therapies.-Fineline Info & Tech